Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
NOVOLOG
Overview
What is NOVOLOG?
NOVOLOG (insulin aspart injection) is a rapid-acting human insulin analog used to lower blood glucose. NOVOLOG is homologous with regular human insulin with the exception of a single substitution of the amino acid proline by aspartic acid in position B28, and is produced by recombinant DNA technology utilizing (baker's yeast). Insulin aspart has the empirical formula CHN0S and a molecular weight of 5825.8.
NOVOLOG is a sterile, aqueous, clear, and colorless solution, that contains insulin aspart 100 Units/mL, glycerin 16 mg/mL, phenol 1.50 mg/mL, metacresol 1.72 mg/mL, zinc 19.6 mcg/mL, disodium hydrogen phosphate dihydrate 1.25 mg/mL, sodium chloride 0.58 mg/mL and water for injection. NOVOLOG has a pH of 7.2-7.6. Hydrochloric acid 10% and/or sodium hydroxide 10% may be added to adjust pH.
What does NOVOLOG look like?
What are the available doses of NOVOLOG?
Each presentation contains 100 Units of insulin aspart per mL (U-100)
What should I talk to my health care provider before I take NOVOLOG?
How should I use NOVOLOG?
NOVOLOG is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.
Subcutaneous injection ():
o
o
o
Continuous Subcutaneous Infusion (Insulin Pump) ():
o
o
o
Intravenous Administration ()
o
o
•
2.4
•
2.4
What interacts with NOVOLOG?
Sorry No Records found
What are the warnings of NOVOLOG?
Sorry No Records found
What are the precautions of NOVOLOG?
Sorry No Records found
What are the side effects of NOVOLOG?
Sorry No records found
What should I look out for while using NOVOLOG?
NOVOLOG is contraindicated:
What might happen if I take too much NOVOLOG?
Excess insulin administration may cause hypoglycemia and hypokalemia . Mild episodes of hypoglycemia usually can be treated with oral glucose. Adjustments in drug dosage, meal patterns, or exercise may be needed. More severe episodes with coma, seizure, or neurologic impairment may be treated with intramuscular/subcutaneous glucagon or concentrated intravenous glucose. Sustained carbohydrate intake and observation may be necessary because hypoglycemia may recur after apparent clinical recovery. Hypokalemia must be corrected appropriately.
How should I store and handle NOVOLOG?
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].Product: 50090-1664NDC: 50090-1664-0 10 mL in a VIAL, GLASS Product: 50090-1665NDC: 50090-1665-0 3 mL in a CARTRIDGE Product: 50090-1678NDC: 50090-1678-0 3 mL in a SYRINGE, PLASTIC Product: 50090-1664NDC: 50090-1664-0 10 mL in a VIAL, GLASS Product: 50090-1665NDC: 50090-1665-0 3 mL in a CARTRIDGE Product: 50090-1678NDC: 50090-1678-0 3 mL in a SYRINGE, PLASTIC Product: 50090-1664NDC: 50090-1664-0 10 mL in a VIAL, GLASS Product: 50090-1665NDC: 50090-1665-0 3 mL in a CARTRIDGE Product: 50090-1678NDC: 50090-1678-0 3 mL in a SYRINGE, PLASTIC Product: 50090-1664NDC: 50090-1664-0 10 mL in a VIAL, GLASS Product: 50090-1665NDC: 50090-1665-0 3 mL in a CARTRIDGE Product: 50090-1678NDC: 50090-1678-0 3 mL in a SYRINGE, PLASTIC Product: 50090-1664NDC: 50090-1664-0 10 mL in a VIAL, GLASS Product: 50090-1665NDC: 50090-1665-0 3 mL in a CARTRIDGE Product: 50090-1678NDC: 50090-1678-0 3 mL in a SYRINGE, PLASTIC Product: 50090-1664NDC: 50090-1664-0 10 mL in a VIAL, GLASS Product: 50090-1665NDC: 50090-1665-0 3 mL in a CARTRIDGE Product: 50090-1678NDC: 50090-1678-0 3 mL in a SYRINGE, PLASTIC
